NSEPress Release2 Jul 2026 · 2 Jul 2026, 08:35 am
Press Release
Glenmark Pharmaceuticals Limited · GLENMARK
✦ AI SummaryExpansion
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer". The company announced the advancement of its multi-country Phase 3 clinical trial for Trastuzumab rezetecan, a HER2-targeted antibody drug conjugate, for patients with platinum-resistant ovarian cancer.
Analysis Scores
Earnings Impact2/10
Growth Catalyst8/10
Governance Concern1/10
Regulatory Risk2/10
Balance Sheet Risk1/10
Liquidity Impact5/10
Market Sentiment5/10
Full Announcement
Glenmark Pharmaceuticals Limited has informed the Exchange regarding a press release dated July 02, 2026, titled "Glenmark Advances Multi-Country Phase 3 Clinical Trial of Trastuzumab rezetecan in Platinum-Resistant Ovarian Cancer".